enzastaurin has been researched along with ruboxistaurin in 5 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (ruboxistaurin) | Trials (ruboxistaurin) | Recent Studies (post-2010) (ruboxistaurin) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 203 | 29 | 56 |
| Protein | Taxonomy | enzastaurin (IC50) | ruboxistaurin (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.6484 | |
| Protein kinase C gamma type | Homo sapiens (human) | 0.3 | |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Homo sapiens (human) | 0.0054 | |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.2 | |
| Protein kinase C alpha type | Homo sapiens (human) | 0.36 | |
| Protein kinase C eta type | Homo sapiens (human) | 0.052 | |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 0.6 | |
| Protein kinase C delta type | Homo sapiens (human) | 0.25 | |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | 0.1 | |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | 0.32 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bach, S; Cahill, MM; Marchand, P; McCarthy, FO; O'Shea, KD; Pierce, LT; Robert, T; Ruchaud, S; Winfield, HJ | 1 |
| Alaoui-Jamali, MA; Amzil, H; Bijian, K; Lim, FPL; Miron, CE; Moitessier, N; Nivedha, AK; Su, J; Wernic, D | 1 |
| Bhat, J; Grewal, BK; Sobhia, ME | 1 |
5 other study(ies) available for enzastaurin and ruboxistaurin
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glycogen Synthase Kinase 3; Humans; Maleimides; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship | 2018 |
Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.
Topics: Antineoplastic Agents; Aurora Kinase A; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Hydrogen Bonding; Isoenzymes; Molecular Docking Simulation; Protein Kinase C; Protein Kinase Inhibitors; Selenium Compounds; Small Molecule Libraries; Structure-Activity Relationship; Substrate Specificity; Tumor Stem Cell Assay | 2022 |
Molecular dynamics approach to probe PKCβII-ligand interactions and influence of crystal water molecules on these interactions.
Topics: Adenosine Triphosphate; Binding Sites; Crystallization; Indoles; Ligands; Maleimides; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase C beta; Protein Kinase Inhibitors; Water | 2015 |